Official website (https://www.biogen.com/)
Biogen
Sign in to saveAlso known as Biogen Inc., BIIB, Biogen Idec
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0
Key facts
- Company.name
- Biogen Inc.
- Company.logo
- Biogen.svg
- Company.logo_size
- 250px
- Company.image
- Biogen.jpg
- Company.image_size
- 240px
- Company.image_caption
- Headquarters in Cambridge, Massachusetts
- Company.former_name
- Biogen Idec Inc. (2003–2015)
- Company.type
- Public
- Company.industry
- Biotechnology
- Company.revenue
- (2025)
- Company.operating_income
- US$1.86billion (2025)
- Company.net_income
- US$1.29billion (2025)
- Company.assets
- US$29.4billion (2025)
- Company.equity
- US$18.3billion (2025)
- Company.num_employees
- 7,500 (2025)
via Wikipedia infobox
Company
BIIB- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- Nasdaq
- State of incorporation
- DE
- Entity type
- operating
- Latest filing
- SCHEDULE 13D/A · 2026-05-14
via SEC EDGAR
Research organization · ROR
- Type
- Company, Funder
- Founded
- 1978
- Location
- Cambridge, United States
- Also known as
- Biogen Idec
- Status
- Active
GRID grid.417832.b · ISNI 0000 0004 0384 8146
Official website
Home | Biogen
Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
biogen.com →Link to the official site · 25,457 chars · not written by Vinony
Wikidata facts
- Revenue
- 10173400000
- Official website
- www.biogen.com
- Image
- Biogen.jpg
Show 6 more facts
- inception
- 1978-00-00
- social media followers
- 10000
- Commons category
- Biogen
- net profit
- 3046900000
- operating income
- 2840700000
- short name
- Biogen
Sources (9)
via Wikidata · CC0
~20 min read
Article
14 sectionsContents
- History
- 2000s
- 2010s
- 2020s
- Conference super spreadaer event during COVID-19 pandemic
- Aducanumab
- Acquisition history
- Finances
- Products
- Pipeline
- Lawsuits
- See also
- References
- External links
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.
On the map
3 mapped locations